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COVID-19 might have affected the care and outcomes of hospitalised acute myocardial 
infarction (AMI). We aimed to determine whether the COVID-19 pandemic changed patient 
response, hospital treatment and mortality from AMI. 
Methods and Results  
Admission were classified as non ST-elevation myocardial infarction (NSTEMI) or STEMI at 
99 hospitals in England through live feeding from the Myocardial Ischaemia National Audit 
Project between 1st January, 2019 and 22nd May, 2020. Time series plots were estimated using 
a 7-day simple moving average, adjusted for seasonality. From 23rd March, 2020 (UK 
lockdown) median daily hospitalisations decreased more for NSTEMI (69 to 35; IRR 0.51, 
95% CI 0.47-0.54) than STEMI (35 to 25; IRR 0.74, 95% CI 0.69-0.80) to a nadir on 19th 
April, 2020. During lockdown, patients were younger (mean age 68.7 years vs. 66.9 years), 
less frequently diabetic (24.6% vs. 28.1%) or had cerebrovascular disease (7.0% vs. 
8.6%). STEMI more frequently received primary PCI (81.8% vs 78.8%%), thrombolysis was 
negligible (0.5% vs. 0.3%), median admission-to-coronary angiography duration for NSTEMI 
decreased (26.2 vs. 64.0 hours), median duration of hospitalisation decreased (4 to 2 days), 
secondary prevention pharmacotherapy prescription remained unchanged (each >94.7%). 
Mortality at 30 days increased for NSTEMI (from 5.4% to 7.5%; OR 1.41, 95% CI 1.08-1.80), 
but decreased for STEMI (from 10.2% to 7.7%; OR 0.73, 95% CI 0.54-0.97).  
Conclusions 
During COVID-19, there was a substantial decline in admissions with AMI. Those who 
presented to hospital were younger, less co-morbid and, for NSTEMI, had higher 30-day 
mortality.   
Introduction 
To reduce the spread of COVID-19, many countries have imposed social containment 
mandates (so called ‘lockdown’), which have resulted in a dramatic decline in local population 










a decline in patients with AMI presenting to hospital during this period, and some have 
suggested that people with symptoms of AMI may be delaying, or not, seeking help from the 
emergency medical services.3-8 Equally, in preparation for, and in response to, the large 
numbers of patients admitted with probable COVID-19, hospitals have undertaken major 
reorganisation of their emergency care facilities, including cardiac catheterisation laboratories. 
The Chinese Society of Cardiology (CSC) expert consensus statement recommended medical 
management for the majority of patients presenting with non-ST-elevation myocardial 
infarction (NSTEMI), and thrombolysis in those presenting with STEMI during the COVID-
19 pandemic9. In contrast, in North America and Canada it has been proposed that thrombolysis 
may be used as an alternative to primary percutaneous coronary intervention (PCI) for patients 
with STEMI where restriction in regular services exist, and in the United Kingdom (UK) that 
primary PCI should remain the preferred reperfusion strategy.10-12  
To date, evidence concerning the presentation, care and outcomes from AMI during the 
COVID-19 pandemic is limited. Information has been derived from single centres or small 
groups of hospitals or, in studies involving routine health system data, have limited information 
about prognostic characteristics of patients including details of the baseline risk, co-morbidities, 
call-for-help times, investigations and guideline-indicated treatments and clinical outcomes, 
particularly from a national perspective.13, 14 An understanding of how COVID-19 lockdown 
may have influenced the health seeking behaviour of patients with AMI as well as the delivery 
of care by specialist services is important if widespread unintended consequences of the 
pandemic are to be minimised and preparations made for a potential second wave.  To that end, 
the Chief Scientific Advisor to the Government of the United Kingdom commissioned the 
National Institute for Cardiovascular Outcomes Research to produce a report to support the 
response of the Department of Health to the COVID-19 pandemic in the UK. This investigation 
details the first national insights around the patient and healthcare response to AMI during and 
in the recovery phase of the COVID-9 pandemic. It will also provide updated time series 
summary data [When published this word will have a hyperlink to 
cardiovascularcovid.leeds.ac.uk] to monitor the progress of AMI patient characteristics, care 
and outcomes during the current COVID19 pandemic in England.  
 
Methods 










The Myocardial Ischaemia National Audit Project (MINAP) is a comprehensive clinical 
database of patients hospitalised with AMI, mandated by the UK Department of Health for all 
hospitals in England. 15-17 Data are collected prospectively at each hospital, electronically 
encrypted and transferred online to a central database at the National Institute for 
Cardiovascular Outcomes Research (NICOR). During COVID-19 pandemic, MINAP data was 
obtained through weekly live feeding into NHS Digital server.  
The analytical cohort was derived from patients with AMI admitted to one of 180 acute 
NHS hospitals in England between 1st January, 2017 and 22nd May, 2020. Patients were eligible 
for the study if they were aged 18 to 100 years and admitted to a NHS hospital in England with 
a final diagnosis of STEMI or NSTEMI. The final diagnosis was determined by local clinicians 
according to presenting history, clinical examination and the results of inpatient investigations 
in keeping with the consensus document of the Joint European Society of Cardiology and 
American College of Cardiology.18 Recurrent events of AMI for patients who had had an AMI 
within 30 days of their previous admission were excluded, as these were considered potential 
complications / adverse outcomes of the index event.  
Time of symptom onset was defined as the time within 10 minutes of when symptoms 
began, and if there was a prodrome of intermittent pain, the time of onset of those symptoms 
that led the patient to call for help. For the derivation of symptom to call-for–help duration, 
only patients who presented to hospital by ambulance were included. Where admission 
followed an out of hospital cardiac arrest, with no better information available, the time of the 
arrest was used for the onset of symptoms. The time of hospital admission was defined as the 
time of arrival of the ambulance at the hospital, or the accident and emergency department 
registration time for patients who self-presented to the department.  
Statistical Analyses 
Baseline characteristics were described using numbers and percentages (with 95% 
confidence interval (CI) of the percentages) for categorical data and means and standard 
deviations (SD) or medians and interquartile ranges (IQR) for normal and non-normally 
distributed continuous variables. For NSTEMI, the probability of in-patient all-cause mortality 
was calculated using the GRACE risk score,19 and categorised into low (1 to 108), intermediate 
(109 to 140) and high risk (141 to 372). Time trends of patient and treatment characteristics 










22nd March 2020) with two other periods: a decline phase from 23rd March (UK ‘lockdown’) 
to the nadir in admissions (on 19th April, 2020), and a recovery phase from 20th April 2020 to 
22nd May 2020)) using χ2-squared and t-tests as appropriate to the distributions of the data.  
Visual comparison were also made across other dates including first suspect case (31st 
December 2019), China lockdown (23rd January 2020), World Health Organisation declaration 
of a public health emergency (30th January 2020), and Italy lockdown (2nd March 2020). Counts 
of daily cases were represented as numbers and unadjusted incidence risk ratios (IRR) with 
accompanying 95% CIs. 
For time series plots, a 7-day simple moving average (indicating the mean number of 
daily admissions for that day and the preceding 6 days), adjusted for seasonality, was estimated. 
To provide an estimate of the impact of the COVID-19 pandemic on admissions and the 
provision of services, an interrupted times series using a generalized linear model for a Poisson 
distribution, was fitted and adjusted for seasonality with a harmonic term. A scaling adjustment 
was made after checking for overdispersion, and autocorrelation examined through partial 
autocorrelation function. 
Patient data were deterministically linked to Civil Registration Deaths Data received up 
to 21st June 2020 (final follow-up). 7-day and 30-day unadjusted all-cause mortality were 
reported with accompanying 95% CIs. 
Given the NHS reorganisation aimed at managing COVID-19,20 there may have been a 
reduction in clinical coding and data submission to NICOR, which could mimic a reduction in 
AMI admissions during the period of study. This was mitigated and investigated through a 
number of steps. Regular notifications were actioned by the British Cardiovascular Society and 
British Cardiovascular Intervention Society to its members, and from NICOR to each hospitals’ 
MINAP audit clerk emphasising the importance of inputting and submitting contemporary data 
to NICOR. A survey of each acute NHS hospitals’ MINAP data coding as well as tracking of 
submission status was undertaken, and from this, 99 ‘rapid-reporting’ hospitals who provided 
weekly uploads of MINAP data were identified and used as primary analysis. 
All tests were two-sided, and statistical significance was considered as P<0.05. 











This work was endorsed by the Chief Scientific Advisor to the Government of the UK 
to provide health data intelligence to the Scientific Advisory Group for Emergencies (SAGE) 
- responsible for ensuring timely and coordinated scientific advice is made available to decision 
makers, to inform NHS care. The Secretary of State for Health and Social Care has issued NHS 
Digital with a Notice under Regulation 3(4) of the NHS(Control of Patient Information 
Regulations) 2002 (COPI) to require NHS Digital to share confidential patient information 
with organisations entitled to process this under COPI for COVID-19 purposes. NICOR which 
includes the MINAP registry (Ref: NIGB: ECC 1-06 (d)/2011) has support under section 251 
of the NHS Act 2006 to use patient information for medical research without informed consent. 
For this rapid NHS evaluation, health data linkage was enabled under COVID-19 public health 
NHS England Directions 2020, conferred by Section 254 of the Health and Social Care Act 
2012. The study complies with the Declaration of Helsinki.  
 
Results 
The analytical cohort was drawn from 117,327 patients hospitalised with AMI in 
England during the study period (Supplementary figure 1). Following exclusions, there were 
50,689 patients admitted with AMI to 99 hospitals in England by 22nd May 2020. Data included 
17,246 STEMI and 33,443 NSTEMI.  
Patients with AMI 
From 23rd March, 2020, there was a 42.3% decrease to a nadir on 19th April in the 
number of hospitalisations with AMI, representing a decline in the median daily number of 
admission from 104 to 60 (IRR 0.59, 95% CI 0.56 to 0.61). From the nadir to 22nd May 2020, 
the median number of admission increased to 72 (1.19, 95% CI 1.12 to 1.26), and qualitatively 
plateaued after an initial recovery (Figure 1).  
Patients hospitalised with AMI during the decline phase were younger (66.87 vs 68.69 
years), more frequently male (69.6% vs 67.9%, Table 1) and less frequently had diabetes (24.5% 
vs 28.1%) and cerebrovascular disease (7.1% vs 8.6%, Figure 2). They had a lower median 
creatinine concentrations, less frequently self-presented to hospital without making use of the 
Emergency Ambulance Service (11.4% vs 20.6%) and less frequently had pulmonary oedema 
(2.5% vs 4.4%, Table 2, Figure 3). The median duration in symptom onset to call-for-help and 










remained stable (Table 2). The proportion of patients followed-up by a cardiologist, receiving 
in-patient echocardiography and, referred for cardiac rehabilitation remained very high, as did 
the prescription of secondary prevention pharmacotherapies at the time of discharge from 
hospital (Figure 3). The median length of hospital stay decreased from 4 to 2 days (Table 2), 
and all-cause mortality at 30 days remained stable (Figure 4).  
During the recovery phase (20th April to 22nd May 2020), the patient characteristics of 
admission with AMI were similar to those of patients in the decline phase (Table 1, Figure 2). 
However, there was a partial return to pre-lockdown rates for self-presentations with AMI to 
hospitals (16.7% vs 20.6%) and those with pulmonary oedema (3.7% vs 4.4%, Table 2). Whilst 
the median duration in symptom onset to call-for-help was no different from previous phases, 
the median duration in call-for-help to hospital arrival times for those arriving by ambulance 
was shorter by 4 minutes (Table 2). The proportion of patients seen by a cardiologist, receiving 
in-patient echocardiography, referred for cardiac rehabilitation, and use of secondary 
prevention therapies each remained very high (Table 2, Figure 3). The median length of 
hospital stay increased to 3 days (Figure 3), and all-cause mortality at 30 days remained stable 
(Figure 4). 
Patients with STEMI 
There was a 28.6% decrease to a nadir on 19th April in the number of hospitalisations 
with STEMI representing a decline in the median daily number of admission from 35 to 25 
(IRR 0.74, 95% CI 0.69 to 0.80), and remain stable in recovery phase.  
The profiles care and outcomes of patients hospitalised with STEMI were not different 
from STEMI admitted before lockdown (Supplementary Table 1, Figure 3). There was 
however, a 50% reduction in people self-presenting to hospital in the decline phase (8.2% vs 
4.0%), which increased following the nadir in admissions (5.8%).  During the recovery phase, 
the median duration in call-for-help to hospital arrival times decreased by 3 minutes compared 
with pre-lockdown, and there was an increase in the median in-hospital time to reperfusion by 
4 minutes. The use of primary PCI was very high throughout the study period and a small 
number of STEMI received thrombolysis (0.3%). Over the three time periods, the median 
length of hospital stay changed from 3 to 2 to 3 days, and crude all-cause mortality at 30 days 
decreased from 10.2% pre lockdown to 7.7% in the decline phase and increased to 8.3% in the 
recovery phase (Supplement table 1, Figure 4). 










There was a 49.3% decrease to a nadir on 19th April in the number of hospitalisations 
with NSTEMI representing a decline in the median daily number of admission from 69 to 35 
(IRR 0.51, 95% CI 0.47 to 0.54). From the nadir to 31st May 2020, the median number of 
admission increased to 46 (1.32, 95% CI 1.22 to 1.42) (Figure 1). 
Following lockdown, patients hospitalised with NSTEMI were younger (68.5 vs 70.2 
years) and less frequently had diabetes mellitus (26.7% vs 31.5%), and pulmonary oedema (2.2% 
vs 4.7%, Supplementary Table 2). In the decline phase there was a 3% reduction in the 
proportion of NSTEMI who received an invasive coronary strategy, and less inter-hospital 
transfers for such an approach. However, for those who received an invasive strategy, the 
median time to invasive coronary angiography was reduced from 64 to 26 to 38 hours over the 
three sequential phases (Supplement Table 2). Delays to receipt of an invasive coronary 
strategy for NSTEMI were less likely to be due to catheter laboratory issues and more likely 
due to patient co-morbidities. During the recovery phase, the median call to hospital admission 
duration decreased by 5 minutes. Following lockdown, the proportion seen by a cardiologist, 
the prescription of secondary prevention medications and referral for cardiac rehabilitation 
were maintained at high levels, but the use of in-patient echocardiography was lower in the 
decline phase. Over the three time periods, the median length of hospital stay changed from 5 
to 2 to 3 days. All-cause mortality at 30 days increased from 5.4% pre lockdown to 7.5% in the 
decline phase and decreased to 5.0% in the recovery phase (Figure 4).  
 
Discussion 
The onset of social containment – a state of lockdown – to reduce the spread of 
COVID19 infection has been associated with almost 50% decline in hospitalisations with AMI 
and a significantly higher early mortality for NSTEMI until the nadir of admissions, despite 
high levels of in-hospital care. Although there was an initial recovery in numbers of admission, 
this plateaued and until the end of the study period remained at two thirds of the pre-lockdown 
rate. Given the numbers of AMI not attending hospital (and delays to presentation among those 
admitted), there is likely to be an increase in AMI-related mortality in the community and 
increased heart failure admissions in the near future. Whilst the decline in admissions support 
findings from other data sources,3-8, 14 this investigation identifies the nadir and, of concern, a 
cessation in the recovery trajectory of admissions. It is therefore important that there is ongoing 










There was a greater decline in admissions with NSTEMI. It is probable that patients 
with NSTEMI did not seek medical help because they felt that their symptoms, which are less 
likely to be chest pain or chest discomfort,21 did not warrant the risk of potential exposure to 
the COVID19 infection in hospital. Although we elected to stratify the analyses by date of the 
UK lockdown, it is apparent that the decline in admissions started earlier in 2020, and 
international media coverage of death, overwhelmed hospitals, country-specific lockdowns as 
well as a declaration by the World Health Organisation of a public health emergency led many 
patients with AMI not to go to hospital for fear of catching the COVID19 infection, being 
isolated on a ward without visitors, and through wanting to protect hospitals. In addition, the 
association between increasing age or pre-existing health conditions with poorer outcomes 
following COVID19 infection was well publicised at the start of the pandemic and many 
patients with NSTEMI would have looked upon themselves as being at significant risk by 
virtue of their age and co-morbidity.  
Early mortality increased for NSTEMI, but not STEMI. In the UK, the management of 
STEMI is institutionally operationalised22, as was evidenced by maintenance of very high 
levels of care. The safeguarding of the UK nationwide primary PCI service is in contrast to 
other international recommendations drawn from preliminary information about over-burdened 
services due to the additional workload arising from COVID-19 patients and hospital measures 
imposed to reduce the spread of the infection.8 For NSTEMI, mortality rates increased in the 
decline phase, when fewer patients were attending hospital. It is possible that other factors were 
at play, including a higher co-morbidity burden, more myocardial ischemia and potentially the 
influence of the COVID19 infection. Moreover, there was a decline in NSTEMI with 
pulmonary oedema, which suggests that cases with large areas of myocardial ischemia may 
have died in the community. Although, in-hospital care standards were maintained at a high 
level, we observed a slightly lower use of an invasive coronary strategy and lower inter-hospital 
transfer rates for this strategy during the decline phase, suggesting that perhaps more patients 
were managed medically, who otherwise would have receive an invasive management.  
In contrast to other countries, where recommendations about the management of 
patients with AMI were modified, the UK upheld its processes of care for AMI. This was 
evidenced in all three phases of the period of this study, where the use of evidence-based care 
were very high, and increased slightly for antiplatelet pharmacotherapies. What is more, the 










– indicating that for NSTEMI the duration of time to receive an invasive coronary strategy may 
be dramatically reduced when the ratio of staff and facilities to patients is increased.  
Interrogation of these live data from a national registry of AMI offers the opportunity 
to prepare for future major health crises. First, it is apparent that, prior to Government directives 
about social distancing, the public appeared to react to the international crisis as it unfolded 
through the media. Second, whilst social isolation was recommended for higher risk patients, 
such patients are also at higher risk of AMI. It is important that the public be reminded during 
the recovery phase that they should attend hospital in the event of a medical emergency – a 
message delivered by both Government and health representatives early during the UK 
lockdown. Third, although this investigation was unable to quantify all of the adverse 
consequences associated with the decline and change in presentation of AMI, there is good 
evidence from the literature of higher rates of death, stroke and heart failure when patients with 
AMI do not receive treatment or present late.23 Finally, a latent excess of AMI-related mortality 
and morbidity should be expected and health services prepared in advance.23   
Although the strengths of this linked registry are apparent, we acknowledge the study 
limitations. MINAP does not collect data for all cases of AMI in England24 and for some 
hospitals, there is a lag in data uploading. This may have over-estimated the decline in rates of 
admissions. Nonetheless, we surveyed all acute hospitals in England and encouraged rapid 
reporting. Linkage to the national death registry enabled accurate censorship dates, but given 
the short-follow-up time it is possible that the full impact of the COVID19 pandemic on the 
prognosis of patients admitted with AMI is not apparent.  
  
Conclusion 
Nationwide data from England linked to death registration, show that following the UK 
lockdown due to the COVID19 pandemic there was a halving of admissions with AMI to a 
nadir at about one month suggesting many patients delayed seeking help from the emergency 
services. Despite evidence for enduring high levels of specialist hospital care and there was an 
increase in early deaths for NSTEMI. Given that AMI is common, and that delayed or no 
treatment for AMI is associated with major cardiovascular and cerebrovascular events, 
Governments and health systems across the globe should prepare for an excess of AMI-related 
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Updates of all Figures are available at cardiovascularcovid.leeds.ac.uk 
 
Figure 1: Times series of daily hospitalisations of acute myocardial infarction between 1st 
January 2019 and 22nd May 2020, by STEMI and NSTEMI 
Data from 99 National Health Service hospitals in England.  Lines represent a 7-day simple 
moving average (indicating the mean number of daily admissions for that day and the preceding 
6 days), adjusted for seasonality. The dates of the COVID lockdown including first suspect 
case (31st December 2019), China lockdown (23rd January 2020), World Health Organisation 
declaration of a public health emergency (30th January 2020) and UK lockdown (23rd March 
2020) are shown with a bold vertical line. 
AMI: acute myocardial infarction; STEMI: ST-elevation myocardial infarction; NSTEMI: 
non-ST elevation myocardial infarction 
 
Figure 2: Time series plot of daily hospitalisations with acute myocardial infarction 
between 1st January 2019 and 22nd May 2020 for baseline patient characteristics, by 
STEMI and NSTEMI 
Data from 99 National Health Service hospitals in England.  Lines represent a 7-day simple 
moving average (indicating the mean number of daily admissions for that day and the preceding 
6 days), adjusted for seasonality. The date of the COVID lockdown (23rd March 2020) is shown 
with a bold vertical line. 
STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST elevation myocardial 
infarction 
 
Figure 3: Time series plot of daily hospitalisations with acute myocardial infarction 
between 1st January 2019 and 22nd May 2020 for patient response and hospital care, by 
STEMI and NSTEMI  
Data from 99 National Health Service hospitals in England.  Lines represent a 7-day simple 
moving average (indicating the mean number of daily admissions for that day and the preceding 
6 days), adjusted for seasonality.  The date of the COVID lockdown (23rd March 2020) is shown 
with a bold vertical line. Symptom to call-for help data are only for patients who presented to 
hospital by ambulance. Transfer rate refers to the proportion of patients hospitalised with 










STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST elevation myocardial 
infarction.  
 
Figure 4: Unadjusted all-cause mortality rates at 30 days following admission with 
STEMI and NSTEMI, by pre-lockdown, decline and recovery phases 
Mortality rates were presented with 95% confidence interval. 
AMI: acute myocardial infarction; STEMI: ST-elevation myocardial infarction; NSTEMI: 
non-ST elevation myocardial infarction 
 
Supplementary figure legends 
 





Table 1: Baseline characteristics of patients hospitalised with acute myocardial infarction 
before and following the UK COVID19 lockdown in NHS in England.  
All cells represent numbers of cases (%, 95% CI) unless otherwise stated.  
Data from 99 National Health Service acute hospitals in England.   
Table 2: Treatments and outcomes of patients hospitalised with acute myocardial 
infarction before and following the UK COVID19 lockdown in NHS in England.  
All cells represent numbers of cases (%, 95% CI) unless otherwise stated.  
Data from 99 National Health Service acute hospitals in England.   
Before UK lockdown: 1st January 2019 to 22nd March 2020; AMI: acute myocardial infarction; 
ROSC: return of spontaneous circulation; ACEi/ARB: angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker 











Supplementary table 1: Baseline characteristics, clinical presentation, treatments and 
outcomes of patients admitted with ST-elevation myocardial infarction between 1st 
January 2019 and 22nd May 2020 for 99 NHS hospitals in England 
 
All cells represent numbers of cases (%, 95% CI) unless otherwise stated; AMI: acute 
myocardial infarction; ROSC: return of spontaneous circulation; ACEi/ARB: angiotensin 
converting enzyme inhibitor/angiotensin receptor blocker 
 
 
Supplementary table 2: Baseline characteristics, clinical presentation, treatments and 
outcomes of patients admitted with non-ST-elevation myocardial infarction between 1st 
January 2019 and 22nd May 2020 for 99 NHS hospitals in England  
All cells represent numbers of cases (%, 95% CI) unless otherwise stated; AMI: acute 
myocardial infarction; ROSC: return of spontaneous circulation; ACEi/ARB: angiotensin 
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Table 1: Baseline characteristics for patients hospitalised with acute myocardial infarction in England before and following the UK 
COVID19 lockdown.  
 
AMI before UK lockdown 
AMI between 23/03/2020  
and 19/04/2020 AMI after 20/04/2020 P-trend 
 
n = 46555 n = 1708 n = 2426 
 Age in years, mean (sd) 68.69 (13.55) 66.87 (13.46) 67.60 (13.33) < 0.001 
Male 31580 (67.9%, 67.4-68.3) 1186 (69.6%, 67.3-71.8) 1703 (70.3%, 68.4-72.1) 0.017 
Current smoker 10863 (25.2%, 24.8-25.6) 424 (27.7%, 25.5-30.1) 583 (26.3%, 24.5-28.2) 0.051 
     
Past medical history 
    CABG surgery 3030 (7.3%, 7.1-7.6) 98 (6.7%, 5.5-8.1) 161 (7.6%, 6.5-8.8) 0.587 
Cerebrovascular disease 3584 (8.6%, 8.3-8.9) 104 (7.0%, 5.8-8.5) 168 (7.8%, 6.8-9.1) 0.056 
Chronic renal failure 3241 (7.7%, 7.5-8.0) 117 (7.9%, 6.6-9.4) 152 (7.0%, 6.0-8.2) 0.484 
Congestive heart failure 3174 (7.6%, 7.3-7.8) 101 (6.8%, 5.6-8.2) 146 (6.8%, 5.8-8.0) 0.244 
COPD or asthma 7358 (17.6%, 17.2-18.0) 258 (17.5%, 15.6-19.5) 371 (17.3%, 15.7-19.0) 0.931 
Diabetes mellitus 12597 (28.1%, 27.7-28.5) 396 (24.6%, 22.5-26.8) 611 (26.5%, 24.7-28.3) 0.002 
Hyperlipidaemia 12935 (30.9%, 30.5-31.3) 453 (30.5%, 28.2-33.0) 702 (32.7%, 30.7-34.7) 0.216 
Hypertension 22813 (53.6%, 53.1-54.1) 797 (52.8%, 50.2-55.3) 1172 (53.8%, 51.7-55.9) 0.805 
Peripheral vascular disease 1838 (4.4%, 4.2-4.6) 62 (4.2%, 3.3-5.4) 93 (4.4%, 3.6-5.3) 0.922 
Previous MI 10187 (24.1%, 23.7-24.5) 350 (23.4%, 21.3-25.7) 482 (22.4%, 20.6-24.2) 0.169 
Previous PCI 6679 (16.2%, 15.8-16.5) 237 (16.2%, 14.3-18.2) 340 (16.1%, 14.5-17.7) 0.993 
Data from 99 National Health Service acute hospitals in England.   
Before UK lockdown: 1st January 2019 to 22nd March 2020; all cells represent numbers of cases (%, 95% CI) unless otherwise stated; AMI: acute myocardial infarction; 








/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcaa062/5878960 by guest on 14 August 2020
Table 2. Clinical presentation, treatments and outcomes of patients hospitalised with acute myocardial infarction in England before and 
following the UK COVID19 lockdown. 
 AMI before lockdown 
AMI between 23/03/2020  
and 19/04/2020 AMI after 20/04/2020 P-trend 
 n = 46555 n = 1708 n = 2426 
 Clinical presentation 
    Self-presented to hospital 9608 (20.6%, 20.3-21.0) 195 (11.4%, 10.0-13.0) 406 (16.7%, 15.3-18.3) < 0.001 
Systolic blood pressure, mmHg, mean (sd) 139.48 ( 28.05) 141.07 ( 28.13) 141.81 ( 28.61) < 0.001 
Heart rate, beats per min, median [IQR] 77.00 [66.00-90.00] 78.00 [67.00-91.00] 79.00 [67.00-91.00] < 0.001 
Creatinine, µmol/l, median [IQR]  84.00 [ 71.00-104.00]  83.00 [ 69.00-101.00]  84.00 [ 70.00-102.00] 0.005 
Pre-hospital cardiac arrest 1731 (3.8%, 3.7-4.0) 67 (4.1%, 3.2-5.2) 73 (3.1%, 2.5-3.9) 0.173 
If pre-hospital cardiac arrest: no ROSC  
or return but died in-hospital 532 (30.7%, 28.6-33.0) 15 (22.4%, 13.5-34.5) 24 (32.9%, 22.6-45.0) 0.314 
Electrocardiographic ST-segment elevation 15380 (33.3%, 32.8-33.7) 706 (41.8%, 39.4-44.1) 841 (35.2%, 33.3-37.1) < 0.001 
Pulmonary oedema 1879 (4.4%, 4.2-4.6) 39 (2.5%, 1.8-3.4) 82 (3.7%, 3.0-4.6) < 0.001 
Cardiogenic shock 674 (1.6%, 1.5-1.7) 24 (1.5%, 1.0-2.3) 34 (1.5%, 1.1-2.2) 0.987 
Patient and healthcare response times 
    Symptom to call duration (mins), median [IQR]  79.00 [ 24.00-303.00]  76.50 [ 27.00-299.75]  90.00 [ 30.00-316.00] 0.115 
Call to hospital admission duration (mins), median [IQR]  79.00 [ 60.00-104.00]  80.00 [ 63.00-103.75] 76.00 [59.00-95.00] < 0.001 
Medications at time of discharge     
ACEi/ARB 30284 (94.5%, 94.2-94.7) 1160 (95.1%, 93.7-96.2) 1686 (94.8%, 93.6-95.7) 0.557 
Beta blocker 32248 (96.2%, 96.0-96.4) 1232 (96.9%, 95.8-97.8) 1731 (96.9%, 96.0-97.7) 0.121 
Aspirin 34516 (97.9%, 97.8-98.1) 1314 (98.4%, 97.6-99.0) 1852 (98.4%, 97.7-98.9) 0.193 
Statin 34858 (97.6%, 97.4-97.7) 1322 (97.9%, 97.0-98.6) 1875 (97.6%, 96.8-98.2) 0.730 
Clopidogrel/prasugrel/ticagrelor 34280 (97.5%, 97.4-97.7) 1321 (99.2%, 98.6-99.6) 1857 (99.0%, 98.4-99.4) < 0.001 
In-hospital outcomes 
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In-patient echocardiography 31406 (77.3%, 76.9-77.7) 1118 (76.6%, 74.3-78.7) 1637 (78.5%, 76.6-80.2) 0.361 
Planned follow-up with a cardiologist 30816 (85.4%, 85.0-85.8) 1119 (87.1%, 85.1-88.8) 1604 (87.6%, 85.9-89.0) 0.011 
Length of hospital stay, median [IQR] 4.00 [2.00-7.00] 2.00 [2.00-4.00] 3.00 [2.00-5.00] < 0.001 
7-day mortality 2035 (4.4%, 4.2-4.6) 81 (4.7%, 3.8-5.9) 100 (4.1%, 3.4-5.0) 0.630 
30-day mortality 3268 (7.0%, 6.8-7.3) 129 (7.6%, 6.4-8.9) 149 (6.1%, 5.2-7.2) 0.167 
Data from 99 National Health Service acute hospitals in England.   
Before UK lockdown: 1st January 2019 to 22nd March 2020; all cells represent numbers of cases (%, 95% CI) unless otherwise stated; AMI: acute myocardial infarction; 
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